RU2010152690A - Белки, связывающие рецептор интерлейкина-21 - Google Patents
Белки, связывающие рецептор интерлейкина-21 Download PDFInfo
- Publication number
- RU2010152690A RU2010152690A RU2010152690/10A RU2010152690A RU2010152690A RU 2010152690 A RU2010152690 A RU 2010152690A RU 2010152690/10 A RU2010152690/10 A RU 2010152690/10A RU 2010152690 A RU2010152690 A RU 2010152690A RU 2010152690 A RU2010152690 A RU 2010152690A
- Authority
- RU
- Russia
- Prior art keywords
- antigen binding
- binding fragment
- binding protein
- protein
- antigen
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 5
- 108090000623 proteins and genes Proteins 0.000 title claims 5
- 102000004527 Interleukin-21 Receptors Human genes 0.000 title 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 104
- 102000036639 antigens Human genes 0.000 claims abstract 104
- 108091007433 antigens Proteins 0.000 claims abstract 104
- 239000012634 fragment Substances 0.000 claims abstract 104
- 108091008324 binding proteins Proteins 0.000 claims abstract 102
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 28
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 claims abstract 10
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 claims abstract 10
- 239000002773 nucleotide Substances 0.000 claims abstract 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 8
- 102000023732 binding proteins Human genes 0.000 claims 88
- 210000004027 cell Anatomy 0.000 claims 8
- 101001010593 Homo sapiens Interleukin-21 receptor Proteins 0.000 claims 6
- 230000004663 cell proliferation Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 14
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5550008P | 2008-05-23 | 2008-05-23 | |
| US61/055,500 | 2008-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010152690A true RU2010152690A (ru) | 2012-06-27 |
Family
ID=41112652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010152690/10A RU2010152690A (ru) | 2008-05-23 | 2009-05-26 | Белки, связывающие рецептор интерлейкина-21 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8163884B2 (enExample) |
| EP (1) | EP2297199A1 (enExample) |
| JP (1) | JP2011523849A (enExample) |
| KR (1) | KR20110040773A (enExample) |
| CN (1) | CN102105491A (enExample) |
| AR (1) | AR071885A1 (enExample) |
| AU (1) | AU2009248809A1 (enExample) |
| CA (1) | CA2724915A1 (enExample) |
| CL (1) | CL2009001284A1 (enExample) |
| CO (1) | CO6382184A2 (enExample) |
| IL (1) | IL209328A0 (enExample) |
| MX (1) | MX2010012811A (enExample) |
| MY (1) | MY149448A (enExample) |
| NZ (1) | NZ589330A (enExample) |
| PE (1) | PE20100141A1 (enExample) |
| RU (1) | RU2010152690A (enExample) |
| SA (1) | SA109300315B1 (enExample) |
| TW (1) | TW201000129A (enExample) |
| WO (1) | WO2009143523A1 (enExample) |
| ZA (1) | ZA201008335B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| CN103328509A (zh) * | 2009-12-25 | 2013-09-25 | 积水医疗株式会社 | 人胰岛素测定法和测定试剂 |
| WO2011113027A2 (en) * | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| CN102406937A (zh) | 1999-03-09 | 2012-04-11 | 津莫吉尼蒂克斯公司 | 新的细胞因子zalpha11配体 |
| AU5142300A (en) | 1999-05-18 | 2000-12-05 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
| AU2001253127A1 (en) * | 2000-04-05 | 2001-10-23 | Zymogenetics Inc. | Soluble zalpha11 cytokine receptors |
| AU2001263088B2 (en) | 2000-05-11 | 2006-07-20 | Genetics Institute, Llc. | Mu-1, member of the cytokine receptor family |
| DE60233888D1 (de) * | 2001-11-05 | 2009-11-12 | Zymogenetics Inc | Il-21-antagonisten |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| PT1531850E (pt) * | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| KR20050037552A (ko) * | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| MXPA05010035A (es) | 2003-03-21 | 2005-11-17 | Wyeth Corp | Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21. |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| BRPI0510996A (pt) * | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
| CN101052419A (zh) * | 2004-08-05 | 2007-10-10 | 惠氏公司 | 拮抗白介素－21受体活性 |
| US20060039902A1 (en) | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2008081198A1 (en) | 2007-01-05 | 2008-07-10 | Imperial Innovations Ltd | Blood assays for predicting inflammatory responses |
-
2009
- 2009-05-22 PE PE2009000719A patent/PE20100141A1/es not_active Application Discontinuation
- 2009-05-22 AR ARP090101847A patent/AR071885A1/es not_active Application Discontinuation
- 2009-05-23 SA SA109300315A patent/SA109300315B1/ar unknown
- 2009-05-25 TW TW098117296A patent/TW201000129A/zh unknown
- 2009-05-25 CL CL2009001284A patent/CL2009001284A1/es unknown
- 2009-05-26 CA CA2724915A patent/CA2724915A1/en not_active Abandoned
- 2009-05-26 KR KR1020107028877A patent/KR20110040773A/ko not_active Withdrawn
- 2009-05-26 RU RU2010152690/10A patent/RU2010152690A/ru not_active Application Discontinuation
- 2009-05-26 CN CN200980128968XA patent/CN102105491A/zh active Pending
- 2009-05-26 MY MYPI2010005509A patent/MY149448A/en unknown
- 2009-05-26 WO PCT/US2009/045182 patent/WO2009143523A1/en not_active Ceased
- 2009-05-26 US US12/472,209 patent/US8163884B2/en not_active Expired - Fee Related
- 2009-05-26 NZ NZ589330A patent/NZ589330A/xx not_active IP Right Cessation
- 2009-05-26 JP JP2011510744A patent/JP2011523849A/ja active Pending
- 2009-05-26 EP EP09751751A patent/EP2297199A1/en not_active Withdrawn
- 2009-05-26 MX MX2010012811A patent/MX2010012811A/es active IP Right Grant
- 2009-05-26 AU AU2009248809A patent/AU2009248809A1/en not_active Abandoned
-
2010
- 2010-11-15 IL IL209328A patent/IL209328A0/en unknown
- 2010-11-19 ZA ZA2010/08335A patent/ZA201008335B/en unknown
- 2010-12-22 CO CO10160884A patent/CO6382184A2/es not_active Application Discontinuation
-
2012
- 2012-04-23 US US13/453,090 patent/US20120264919A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009001284A1 (es) | 2009-11-27 |
| CA2724915A1 (en) | 2009-11-26 |
| MX2010012811A (es) | 2011-05-19 |
| WO2009143523A1 (en) | 2009-11-26 |
| MY149448A (en) | 2013-08-30 |
| AU2009248809A1 (en) | 2009-11-26 |
| US20120264919A1 (en) | 2012-10-18 |
| JP2011523849A (ja) | 2011-08-25 |
| US8163884B2 (en) | 2012-04-24 |
| EP2297199A1 (en) | 2011-03-23 |
| SA109300315B1 (ar) | 2012-08-28 |
| KR20110040773A (ko) | 2011-04-20 |
| TW201000129A (en) | 2010-01-01 |
| PE20100141A1 (es) | 2010-02-22 |
| ZA201008335B (en) | 2014-04-30 |
| US20090298167A1 (en) | 2009-12-03 |
| CN102105491A (zh) | 2011-06-22 |
| AR071885A1 (es) | 2010-07-21 |
| NZ589330A (en) | 2012-12-21 |
| CO6382184A2 (es) | 2012-02-15 |
| IL209328A0 (en) | 2011-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2467016C2 (ru) | Антитела к il-22 человека и их применение | |
| RU2010152690A (ru) | Белки, связывающие рецептор интерлейкина-21 | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2009531023A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2011510654A5 (enExample) | ||
| RU2009138922A (ru) | Новые анти-r7v-антитела и их применения | |
| RU2010136940A (ru) | Антитела против альфа5-бета1 и их применение | |
| TW200745164A (en) | Gene recombination antibodies composition | |
| JP2019520809A5 (enExample) | ||
| RU2010123693A (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ | |
| CA2797981A1 (en) | Heterodimeric proteins and methods for producing and purifying them | |
| RU2012149858A (ru) | Получение гетеромультимерных белков | |
| SI2573121T1 (en) | IL-4 and / or IL-13 binding antibodies and their uses | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| RU2011138154A (ru) | Белки специфического связывания и их применения | |
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| JP2014509187A5 (enExample) | ||
| RU2008106893A (ru) | Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул | |
| JPWO2022040482A5 (enExample) | ||
| RU2010129558A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 | |
| HRP20130877T1 (hr) | Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| JP2020505927A5 (enExample) | ||
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140505 |